Generic filters

AMPE – Ampio Pharmaceuticals Inc

Not Compliant

The company’s impure earnings are more than 5% of its total revenues.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The Company is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.


Debt ÷ Market cap (MC)0
Non-Compliant Assets ÷ MC
Impure Income (incl. Interest)5.34
Impure Income%
Interest Income5.34%